ENTO — Entero Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.73m
- $1.57m
- 10
- 59
- 27
- 23
Annual cashflow statement for Entero Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.7 | -58.5 | -14.6 | -15.8 | -18.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 6.73 | 8.61 | 2.76 | 1.2 | 6.26 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 14.2 | 17.1 | -10.5 | 2.19 | 2.53 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -11.2 | -32.3 | -22.3 | -12.4 | -9.22 |
| Capital Expenditures | -0.004 | -0.069 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.092 | -10.3 | 0 | -0.5 | 0.088 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.087 | -10.3 | 0 | -0.5 | 0.088 |
| Financing Cash Flow Items | — | — | -6.91 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17 | 44.8 | 15.7 | 15.2 | 5.58 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 5.89 | 2.19 | -6.86 | 2.35 | -3.55 |